Back to results

Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplant of Pediatric and Adult Patients

Objective

The primary aim of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. The study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of unlicensed, investigational NCBP CBUs.

Protocol #

6637-01

Trial Phase:

Phase II

Principal Investigator:

McCarty, John

Cancer Type
  • Hodgkin's Lymphoma
  • Leukemia
  • not otherwise specified
  • Leukemia
  • other
  • Lymphoid Leukemia
  • Multiple Myeloma
  • Myeloid and Monocytic Leukemia
  • Non-Hodgkin's Lymphoma
  • Other Hematopoietic
Study Site
  • Virginia Commonwealth University

-Patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment are eligible.
-Patients of any age and either gender are eligible.

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Both
  • Protocol Type Treatment
  • Research Study Team Kristin Lantis, MSN, RN, CCRP
    Phone: +1 804-828-2177
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: